申请人:TAISHO PHARMACEUTICAL CO., LTD
公开号:EP1388537A1
公开(公告)日:2004-02-11
An arginine derivative represented by the formula:
[wherein Ar1 and Ar2 may be the same or different, and are each a phenyl group, a substituted phenyl group, a naphthyl group, a substituted naphthyl group or a heteroaromatic ring group containing one or more of nitrogen, oxygen and sulfur atoms; Y1 is a C1-5 alkylene group, a C2-5 alkenylene group or a single bond; and the C1-5 alkylene group optionally contains a carbon atom substituted with a phenyl group, a substituted phenyl group, a naphthyl group, a substituted naphthyl group or a C1-10 acylamino group; Q is a carbonyl group or a sulfonyl group; Y2 is a C1-5 alkylene group; the C1-5 alkylene group optionally contains a carbon atom substituted with a phenyl group, a substituted phenyl group, a naphthyl group, a substituted naphthyl group, a hydroxyl group, a carbamoyl group, a mono-C1-5 alkylamide group or a di-C1-5 alkylamide group], or a pharmaceutically acceptable salt thereof.
There are provided peptidergic ligands which have the affinity and specificity to MC4 receptor.
一种以以下式表示的精氨酸衍生物:[其中Ar1和Ar2可以相同或不同,分别为苯基,取代苯基,萘基,取代萘基或含有一个或多个氮,氧和硫原子的杂环芳基环;Y1为C1-5烷基,C2-5烯基烷基或单键;C1-5烷基可以选用含有苯基,取代苯基,萘基,取代萘基或C1-10酰胺基的碳原子进行取代;Q为羰基或磺酰基;Y2为C1-5烷基;C1-5烷基可以选用含有苯基,取代苯基,萘基,取代萘基,羟基,氨基甲酰基,单C1-5烷基酰胺基或双C1-5烷基酰胺基的碳原子进行取代],或其药学上可接受的盐。提供了具有MC4受体亲和力和特异性的肽类配体。